Objective： To explore the clinical significance of the examination of serum CA125 level of patients with metastatic bladder carcinoma. Methods： Electrochemiluminescence technique was used to examine the serum CA125 ...Objective： To explore the clinical significance of the examination of serum CA125 level of patients with metastatic bladder carcinoma. Methods： Electrochemiluminescence technique was used to examine the serum CA125 concentration of 58 cases with metastatic bladder cancer. 30 cases of superficial bladder cancer and 8 cases of other urological diseases were collected as the control group. Results： Serum CA125 level in 39 （67.2%） out of 58 cases ranged from 36.7 U/mL to 1485.6 U/mL （mean 496.3 U/mL）, being higher than normal （〈 35 U/mL）. Serum CA125 level of metastatic bladder cancer patients was 324.5 U/mL, significantly higher than that in control group （P 〈 0.001）. Serum CA125 level of 10 patients after transurethral resection operation was significantly lower than that before operation （P 〈 0.05）. Serum CA125 level of 16 patients who refused further treatment significantly increased from 450.4 U/mL, to 505.8 U/mL （P = 0.041） 3 months after discharge from the hospital. Serum CA125 level of 17 patients significantly decreased from 475.8 U/L to 237.9 U/mL （P 〈 0.001 ） after bilateral iliac-artedal embolism treatment. Conclusion： CA125 may be a valuable marker for the judgment of advanced metastatic bladder cancer.展开更多
Objective： To study the effect of dendritic cells loaded with whole tumor antigen on hematogenous micrometastasis of bladder cancer model in hu-PBL-SCID mice. Methods： T24-3 ceil subset was selected from human bladd...Objective： To study the effect of dendritic cells loaded with whole tumor antigen on hematogenous micrometastasis of bladder cancer model in hu-PBL-SCID mice. Methods： T24-3 ceil subset was selected from human bladder transitional cell carcinoma T24 cell line by Boyden chamber system. The SCID mice intraperitoneally injected with 4 × 10^7 hu-PBL and subcutaneously injected with 3 × 10^6 T24-3 cells were named hu-PBL-T24-3-SCID model. Human IgG level in the blood plasma of mice was detected by ELISA, and human CD3^＋, CD4^＋, CD8^＋ T cells in blood and spleen cells of mice were detected by FCM analysis for human immune reconstruction study. Human CK20 mRNA expression in mice peripheral blood was detected by RT-PCR to investigate metastasis of tumor cells. The PBMCs were isolated from human peripheral blood, and were induced into DCs by co-culture with rhGM-CSF and rhlL-4 in vitro. The DC vaccines were produced by co-culturing with whole tumor antigen which was purified through freezing and melting T24-3 cell subset. After T24-3 cells injected into SCID mice for 5 weeks, the mice were treated with DC vaccines. Results： All mice were initially treated at 5th week. The expression of CK20 mRNA in peripheral blood of DC vaccines treated mice was the lowest. There was 2 mice showing CK20 mRNA expression and 3 mice with metastasis tumor in PBS group. MMP-7 mRNA expression in tumor tissues of DC vaccines treated mice was statistically lower than that of PBS group （P 〈 0.01）. Conclusion： DC vaccines have a good effect on hu-PBL-SCID mice bladder cancer model by reducing hematogenous micrometastasis.展开更多
文摘Objective： To explore the clinical significance of the examination of serum CA125 level of patients with metastatic bladder carcinoma. Methods： Electrochemiluminescence technique was used to examine the serum CA125 concentration of 58 cases with metastatic bladder cancer. 30 cases of superficial bladder cancer and 8 cases of other urological diseases were collected as the control group. Results： Serum CA125 level in 39 （67.2%） out of 58 cases ranged from 36.7 U/mL to 1485.6 U/mL （mean 496.3 U/mL）, being higher than normal （〈 35 U/mL）. Serum CA125 level of metastatic bladder cancer patients was 324.5 U/mL, significantly higher than that in control group （P 〈 0.001）. Serum CA125 level of 10 patients after transurethral resection operation was significantly lower than that before operation （P 〈 0.05）. Serum CA125 level of 16 patients who refused further treatment significantly increased from 450.4 U/mL, to 505.8 U/mL （P = 0.041） 3 months after discharge from the hospital. Serum CA125 level of 17 patients significantly decreased from 475.8 U/L to 237.9 U/mL （P 〈 0.001 ） after bilateral iliac-artedal embolism treatment. Conclusion： CA125 may be a valuable marker for the judgment of advanced metastatic bladder cancer.
文摘Objective： To study the effect of dendritic cells loaded with whole tumor antigen on hematogenous micrometastasis of bladder cancer model in hu-PBL-SCID mice. Methods： T24-3 ceil subset was selected from human bladder transitional cell carcinoma T24 cell line by Boyden chamber system. The SCID mice intraperitoneally injected with 4 × 10^7 hu-PBL and subcutaneously injected with 3 × 10^6 T24-3 cells were named hu-PBL-T24-3-SCID model. Human IgG level in the blood plasma of mice was detected by ELISA, and human CD3^＋, CD4^＋, CD8^＋ T cells in blood and spleen cells of mice were detected by FCM analysis for human immune reconstruction study. Human CK20 mRNA expression in mice peripheral blood was detected by RT-PCR to investigate metastasis of tumor cells. The PBMCs were isolated from human peripheral blood, and were induced into DCs by co-culture with rhGM-CSF and rhlL-4 in vitro. The DC vaccines were produced by co-culturing with whole tumor antigen which was purified through freezing and melting T24-3 cell subset. After T24-3 cells injected into SCID mice for 5 weeks, the mice were treated with DC vaccines. Results： All mice were initially treated at 5th week. The expression of CK20 mRNA in peripheral blood of DC vaccines treated mice was the lowest. There was 2 mice showing CK20 mRNA expression and 3 mice with metastasis tumor in PBS group. MMP-7 mRNA expression in tumor tissues of DC vaccines treated mice was statistically lower than that of PBS group （P 〈 0.01）. Conclusion： DC vaccines have a good effect on hu-PBL-SCID mice bladder cancer model by reducing hematogenous micrometastasis.
